Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B:A comprehensive review of phases II and III therapeutic agents  

作　　者：Robert Lam Joseph K Lim 

机构地区：[1]Section of Digestive Diseases,Yale University School of Medicine,New Haven,CT 06520,United States

出　　处：《World Journal of Hepatology》2024年第3期331-343,共13页世界肝病学杂志（英文版）（电子版）

摘　　要：Chronic hepatitis B virus(HBV)infection affects over 295 million people globally and an estimated 1.6 million people in the United States.It is associated with significant morbidity and mortality due to cirrhosis,liver failure,and liver cancer.Antiviral therapy with oral nucleos(t)ide analogues is associated with high rates of virologic suppression,which in turn has been associated with a decreased risk of liver complications.However,current antiviral regimens are limited by concerns with adverse effects,adherence,resistance,long-term treatment,and ongoing risk for liver events.Novel investigational agents are currently in development and are targeted at achieving functional cure with sustained hepatitis B surface antigen(HBsAg)loss and suppression of HBV DNA.Herein we review key evidence from phases II and III trials defining the efficacy and safety profiles for key investigational agents for functional cure of chronic hepatitis B,including core/capsid inhibitors,entry inhibitors,RNA interference(siRNA/ASO),HBsAg inhibitors,Toll-like receptor agonists,checkpoint inhibitors,and therapeutic vaccines.

关 键 词：Hepatitis B virus Treatment Clinical trials RNA interference Entry inhibitors Core inhibitors IMMUNOMODULATORS 

分 类 号：R512.62[医药卫生—内科学]